NCT07549386已完成3 期
Efficacy and Safety of Etoricoxib 90 mg + Diacerein 50 mg Capsule Compared to Meloxicam 15 mg + Diacerein 50 mg in Patients With Knee and/or Hip Osteoarthritis: a Phase III, Controlled, Randomized, Double-blind, Multicenter Clinical Trial.
Laboratorios Liomont4 个研究点 分布在 1 个国家目标入组 123 人开始时间: 2024年5月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 123
- 试验地点
- 4
- 主要终点
- Pain intensity change
研究概览
简要总结
The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoathritis-associated pain in adults. It will also learn about the safety of the drug. The main questions it aims to answer are:
Does etoricoxib+diacerein reduces pain intensity as per WOMAC scale after 60 days? What medical problems do participants have when taking etoricoxib 90 mg+diacerein 50 mg capsule during 60 days? Researchers will compare the test drug etoricoxib 90 mg+diacerein 50 mg capsule to an actice comparator (meloxicam 15 mg + diacereina 50 mg) to see if drug ABC works to treat pain in patients with osteoathritis.
Participants will:
Take drug the test or comparator drugs every day for 60 days. Visit the clinic once a month for health and outcomes follow-up. Keep a diary of their symptoms, pain intensity, WOMAC scale, adverse events, rescue medication use, other used drugs, and treatment adherence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult men and women (≥ 18 and ≤ 65 years of age).
- •Patients who agree to participate in the study by signing the informed consent form.
- •Patients with a clinical diagnosis of knee or hip OA according to the American College of Rheumatology criteria with radiographic evidence of OA (K-L score ≥2) in the index joint (defined as the joint with OA being evaluated in this study).
- •A joint previously treated by joint replacement surgery cannot be considered an index joint.
- •A joint surgically intervened within the previous year cannot be considered an index joint.
- •If a patient has a K-L score of ≥2 in more than one joint (knees or hip), the index joint will be the joint with the highest WOMAC pain subscore.
- •If two or more of the patient's joints (knees or hip) have a K-L score of ≥2 and the same WOMAC pain subscore, the index joint will be the joint with the highest K-L score.
- •If two or more joints (knees or hip) have a K-L score of ≥2, the same WOMAC pain subscore, and the same K-L score, the investigator may choose one of these joints as the index joint based on medical judgment.
- •Patients with moderate to severe pain in the index joint defined as a WOMAC pain subscore of ≥
- •Patients who, in the investigator's medical judgment, can discontinue current analgesic medications and are willing to comply with the study requirements.
排除标准
- •Patients with allergy or hypersensitivity to the study medications (including the rescue medication) or to any of their excipients.
- •Patients with a body mass index ≥
- •Patients with a history of rapidly progressive hip OA.
- •Patients with a history of inflammatory joint disease other than OA (e.g., rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudogout, acute gout, joint infections) or seronegative spondyloarthropathy, Paget's disease of the spine, pelvis, or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, spinal cord tumors or infections, or renal osteodystrophy.
- •History of arthropathy (osteonecrosis, insufficiency fracture of subchondral bone, rapidly progressive osteoarthritis type 1 or type 2), neuropathic joint arthropathy, hip dislocation, knee dislocation, extensive subchondral cysts, significant bone collapse, significant loss of bone mass, or pathological fractures.
- •Scheduled joint replacement surgery to be performed during the study period, or arthroscopic procedures within 6 months prior to study initiation.
- •Trauma to the index joint within 30 days prior to the screening visit.
- •Use of systemic corticosteroids within 30 days prior to the screening visit or intra-articular corticosteroids in the index joint within 12 weeks prior to the screening visit.
- •Concomitant use of medications with laxative effects.
- •Continuous oral treatment (at least 90 days) with a SYSADOA medication (chondroitin sulfate, glucosamine sulfate, diacerein, or other) within 3 months before the start of the study.
- •Use of monoamine reuptake inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors for pain treatment within 4 weeks prior to the screening visit.
- •History of peptic ulcer or gastrointestinal bleeding within 12 months prior to the screening visit and/or medical contraindication for the use of NSAIDs.
- •Severe gastrointestinal disorders, including persistent diarrhea (≥3 bowel movements/24 hours).
- •Renal insufficiency (serum creatinine ≥1.8 mg/dL or 2+ proteinuria on a test or a glomerular filtration rate <30 mL/min).
- •Liver enzyme levels (ALT, AST, GST) elevated ≥2.5 times the upper limit of normal at the time of screening.
- •History or presence of cardiovascular diseases (e.g., second- or third-degree heart block, first-degree heart block with abnormal QRS or bifascicular block, history of uncontrolled arterial hypertension, congestive heart failure classified as NYHA stage II-IV, transient ischemic attack (TIA) or stroke within 12 months prior to the screening visit, or myocardial infarction or acute coronary syndromes or evidence of peripheral vascular insufficiency with claudication within 6 months prior to the screening visit).
- •History of other comorbidities that, in the investigator's judgment, could affect the subject's participation in the study, their safety, or the outcome of the study variables.
- •Current history of alcoholism and/or drug abuse.
- •Current participation in a clinical research study evaluating another investigational drug or having received another investigational product within 30 days prior to the screening visit.
- •Women with a positive pregnancy test at the time of screening or who are breastfeeding.
研究组 & 干预措施
Etoricoxib 90 mg + diacerein 50 mg
Experimental
One capsule
干预措施: Etoricoxib 90 mg + diacerein 50 mg (Drug)
Meloxicam 15 mg + diacerein 50 mg
Active Comparator
One capsule
干预措施: Etoricoxib 90 mg + diacerein 50 mg (Drug)
结局指标
主要结局
Pain intensity change
时间窗: At 60 days from baseline
Pain intensity change measured by 100 mm - Visual Analogue Scale. A reduction of 20 mm or higher means a clinically relevant outcome.
次要结局
- Osteoarthritis index change(At 60 days from baseline)
- Use of rescue medication(At 60 days from baseline.)
- Quality of Life(At 60 days from baseline.)
- Safety and tolerability(At 60 days from informed consent sign.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and SynovitisBursitisTendinitisSynovitisNCT07328022Laboratorios Silanes S.A. de C.V.89
招募中
3 期
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisNCT07321093Biocad292
招募中
1 期
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)NCT07290244Life Biosciences Inc.18
招募中
1 期
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesAutoimmune Hemolytic AnemiaNCT07441525Union Hospital, Tongji Medical College, Huazhong University of Science and Technology27
进行中（未招募）
不适用
Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCLNCT07393204Andrés José Maria Ferreri150